<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04283240</url>
  </required_header>
  <id_info>
    <org_study_id>1-10-72-282-14</org_study_id>
    <nct_id>NCT04283240</nct_id>
  </id_info>
  <brief_title>Sildenafil in Acute Pulmonary Embolism</brief_title>
  <acronym>YGGDRASIL</acronym>
  <official_title>Pulmonary Vasodilation by Sildenafil in Acute Pulmonary Embolism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate if acute pulmonary vasodilation by sildenafil improves right ventricular
      function in patients with acute intermediate-high risk pulmonary embolism (PE).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with PE randomized to a single oral dose of sildenafil 50mg (n=10) or placebo (n=10)
      as add-on to conventional therapy. Right ventricular function evaluated immediately before
      and shortly after (0.5-1.5h) randomization by right heart catheterization (RHC),
      trans-thoracic echocardiography (TTE), and cardiac magnetic resonance (CMR). The primary
      efficacy endpoint was cardiac index measured by CMR.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2015</start_date>
  <completion_date type="Actual">September 10, 2018</completion_date>
  <primary_completion_date type="Actual">September 10, 2017</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Treatment was blinded by the institutional pharmacy embedding the placebo or treatment pill in a gelatinous cap</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiac Index</measure>
    <time_frame>74 (plus/minus 17) minutes after drug administration</time_frame>
    <description>Cardiac Index measured by cardiac magnetic resonance imaging</description>
  </primary_outcome>
  <other_outcome>
    <measure>Right ventricular stroke volume</measure>
    <time_frame>74 (plus/minus 17) minutes after drug administration</time_frame>
    <description>Evaluated by cardiac magnetic resonance imaging</description>
  </other_outcome>
  <other_outcome>
    <measure>Cardiac output</measure>
    <time_frame>74 (plus/minus 17) minutes after drug administration</time_frame>
    <description>Evaluated by cardiac magnetic resonance imaging</description>
  </other_outcome>
  <other_outcome>
    <measure>Right ventricular end diastolic volume</measure>
    <time_frame>74 (plus/minus 17) minutes after drug administration</time_frame>
    <description>Evaluated by cardiac magnetic resonance imaging</description>
  </other_outcome>
  <other_outcome>
    <measure>Right ventricular end systolic volume</measure>
    <time_frame>74 (plus/minus 17) minutes after drug administration</time_frame>
    <description>Evaluated by cardiac magnetic resonance imaging</description>
  </other_outcome>
  <other_outcome>
    <measure>Right ventricular ejection fraction</measure>
    <time_frame>74 (plus/minus 17) minutes after drug administration</time_frame>
    <description>Evaluated by cardiac magnetic resonance imaging</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean longitudinal strain</measure>
    <time_frame>74 (plus/minus 17) minutes after drug administration</time_frame>
    <description>Evaluated by cardiac magnetic resonance imaging</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean pulmonary capillary wedge pressure</measure>
    <time_frame>32 (plus/minus 5 min) minutes after drug administration</time_frame>
    <description>Evaluated by Right heart catheterization</description>
  </other_outcome>
  <other_outcome>
    <measure>diastolic pulmonary artery pressure</measure>
    <time_frame>32 (plus/minus 5 min) minutes after drug administration</time_frame>
    <description>Evaluated by Right heart catheterization</description>
  </other_outcome>
  <other_outcome>
    <measure>systolic pulmonary artery pressure</measure>
    <time_frame>32 (plus/minus 5 min) minutes after drug administration</time_frame>
    <description>Evaluated by Right heart catheterization</description>
  </other_outcome>
  <other_outcome>
    <measure>mean pulmonary artery pressure</measure>
    <time_frame>32 (plus/minus 5 min) minutes after drug administration</time_frame>
    <description>Evaluated by Right heart catheterization</description>
  </other_outcome>
  <other_outcome>
    <measure>Pulmonary vascular resistance</measure>
    <time_frame>32 (plus/minus 5 min) minutes after drug administration</time_frame>
    <description>Evaluated by Right heart catheterization</description>
  </other_outcome>
  <other_outcome>
    <measure>Venous oxygen saturation</measure>
    <time_frame>32 (plus/minus 5 min) minutes after drug administration</time_frame>
    <description>Evaluated by Right heart catheterization</description>
  </other_outcome>
  <other_outcome>
    <measure>Right ventricular/left ventricular diameter</measure>
    <time_frame>84 (plus/minus 40) minutes after drug administration</time_frame>
    <description>Evaluated by echocardiography</description>
  </other_outcome>
  <other_outcome>
    <measure>Right ventricular fractional area change</measure>
    <time_frame>84 (plus/minus 40) minutes after drug administration</time_frame>
    <description>Evaluated by echocardiography</description>
  </other_outcome>
  <other_outcome>
    <measure>Tricuspid annular plane systolic excursion</measure>
    <time_frame>84 (plus/minus 40) minutes after drug administration</time_frame>
    <description>Evaluated by echocardiography</description>
  </other_outcome>
  <other_outcome>
    <measure>Pulmonary artery acceleration time</measure>
    <time_frame>84 (plus/minus 40) minutes after drug administration</time_frame>
    <description>Evaluated by echocardiography</description>
  </other_outcome>
  <other_outcome>
    <measure>Tricuspid regurgitant gradient</measure>
    <time_frame>84 (plus/minus 40) minutes after drug administration</time_frame>
    <description>Evaluated by echocardiography</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Pulmonary Embolism</condition>
  <arm_group>
    <arm_group_label>Sildenafil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>50 mg sildenafil oral. One dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo pill. One dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sildenafil</intervention_name>
    <description>50 mg sildenafil, one dose</description>
    <arm_group_label>Sildenafil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with acute pulmonary embolism confirmed by contrast enhanced computed
             tomography (CT)

          -  symptom duration of less than 14 days

          -  older than 18-80 years

          -  right ventricular/left ventricular ratio (RV/LV) &gt;1 measured by trans-thoracic
             echocardiography (TTE, 1 cm above the atrio-ventricular valves in the four-chamber
             view at end-diastole).

        Exclusion Criteria:

          -  pregnant

          -  cardiac arrest that required cardiopulmonary resuscitation

          -  a life expectancy &lt;120 days

          -  systolic blood pressure &lt;90 mmHg

          -  metal implants, obesity or claustrophobia that excluded the patient from cardiac
             magnetic resonance (CMR)

          -  altered mental status making the patient unable to provide informed consent

          -  recent use of drugs with influence on the Nitric oxide-cyclic guanosine monophosphate
             pathway

          -  known or suspected chronic thromboembolic pulmonary hypertension

          -  inability to perform study protocol &lt; 72 hours after conventional PE treatment was
             instituted

          -  active bleeding after thrombolysis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>80 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Asger Andersen, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aarhus University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 7, 2020</study_first_submitted>
  <study_first_submitted_qc>February 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 25, 2020</study_first_posted>
  <last_update_submitted>February 21, 2020</last_update_submitted>
  <last_update_submitted_qc>February 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Embolism</mesh_term>
    <mesh_term>Embolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sildenafil Citrate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>By request</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

